Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fengjiao Hu

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Scientific Reports|March 8, 2025
Targeted imaging of pulmonary fibrosis by a cyclic peptide LyP-1Jing Li, Rui Shu, Tian Peng, et al.
Journal of the American Heart Association|March 25, 2026
Association Between Questionnaire- and Accelerometer-Based Physical Activity and Abdominal Aortic Aneurysm IncidenceRu Li, Fang Lei, Bo Liu, et al.
Journal of Hepatology|October 17, 2021
Hepatocyte glutathione S-transferase mu 2 prevents non-alcoholic steatohepatitis by suppressing ASK1 signalingTian Lan, Yufeng Hu, Fengjiao Hu, et al.
Hepatology (Baltimore, Md.)|July 17, 2021
The E3 Ubiquitin Ligase Ring Finger Protein 5 Ameliorates NASH Through Ubiquitin-Mediated Degradation of 3-Hydroxy-3-Methylglutaryl CoA Reductase Degradation Protein 1Qin Yang, Xi Chen, Yanfang Zhang, et al.
Hepatology (Baltimore, Md.)|August 26, 2021
A conventional immune regulator mitochondrial antiviral signaling protein blocks hepatic steatosis by maintaining mitochondrial homeostasisJiajun Fu, Fengjiao Hu, Tengfei Ma, et al.
Hypertension (Dallas, Tex. : 1979)|July 21, 2020
Ca<sup>2+</sup>-Dependent NOX5 (NADPH Oxidase 5) Exaggerates Cardiac Hypertrophy Through Reactive Oxygen Species ProductionGuo-Jun Zhao, Chang-Ling Zhao, Shan Ouyang, et al.
Hepatology (Baltimore, Md.)|July 7, 2021
Fatty Acid Synthase-Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLDYufeng Hu, Wenzhi He, Yongping Huang, et al.
Hepatology (Baltimore, Md.)|February 13, 2022
FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axisLintao Song, Luyao Wang, Yushu Hou, et al.
Hepatology (Baltimore, Md.)|April 24, 2021
Hepatocyte SH3RF2 Deficiency Is a Key Aggravator for NAFLDXia Yang, Dating Sun, Hui Xiang, et al.
Circulation Research|April 19, 2022
The E3 Ligase TRIM16 Is a Key Suppressor of Pathological Cardiac HypertrophyJiayi Liu, Wei Li, Ke-Qiong Deng, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Scientific Reports|March 8, 2025
Targeted imaging of pulmonary fibrosis by a cyclic peptide LyP-1Jing Li, Rui Shu, Tian Peng, et al.
Journal of the American Heart Association|March 25, 2026
Association Between Questionnaire- and Accelerometer-Based Physical Activity and Abdominal Aortic Aneurysm IncidenceRu Li, Fang Lei, Bo Liu, et al.
Journal of Hepatology|October 17, 2021
Hepatocyte glutathione S-transferase mu 2 prevents non-alcoholic steatohepatitis by suppressing ASK1 signalingTian Lan, Yufeng Hu, Fengjiao Hu, et al.
Hepatology (Baltimore, Md.)|July 17, 2021
The E3 Ubiquitin Ligase Ring Finger Protein 5 Ameliorates NASH Through Ubiquitin-Mediated Degradation of 3-Hydroxy-3-Methylglutaryl CoA Reductase Degradation Protein 1Qin Yang, Xi Chen, Yanfang Zhang, et al.
Hepatology (Baltimore, Md.)|August 26, 2021
A conventional immune regulator mitochondrial antiviral signaling protein blocks hepatic steatosis by maintaining mitochondrial homeostasisJiajun Fu, Fengjiao Hu, Tengfei Ma, et al.
Hypertension (Dallas, Tex. : 1979)|July 21, 2020
Ca<sup>2+</sup>-Dependent NOX5 (NADPH Oxidase 5) Exaggerates Cardiac Hypertrophy Through Reactive Oxygen Species ProductionGuo-Jun Zhao, Chang-Ling Zhao, Shan Ouyang, et al.
Hepatology (Baltimore, Md.)|July 7, 2021
Fatty Acid Synthase-Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLDYufeng Hu, Wenzhi He, Yongping Huang, et al.
Hepatology (Baltimore, Md.)|February 13, 2022
FGF4 protects the liver from nonalcoholic fatty liver disease by activating the AMP-activated protein kinase-Caspase 6 signal axisLintao Song, Luyao Wang, Yushu Hou, et al.
Hepatology (Baltimore, Md.)|April 24, 2021
Hepatocyte SH3RF2 Deficiency Is a Key Aggravator for NAFLDXia Yang, Dating Sun, Hui Xiang, et al.
Circulation Research|April 19, 2022
The E3 Ligase TRIM16 Is a Key Suppressor of Pathological Cardiac HypertrophyJiayi Liu, Wei Li, Ke-Qiong Deng, et al.
Pageof 5